Chemi-Luminescence ImmunoAssay (CLIA) for the quantitative determination of IgA antibodies to SARS-CoV-2 Nucleocapsid protein (NCP) in human plasma and sera.
The kit is intended for monitoring of infected patients.
In addition, the kit may be used when testing the population and health-care workers looking for potentially infective “pauci” or a-symptomatic individuals in the early phase of infection, in combination with SARS-COV-2 molecular tests.
The device has been adapted for the use in exclusive combination with the Dia.Pro CLIA random access instrument named SARA.